GSK3117391 / GSK, Chroma Therap - LARVOL DELTA

Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - P2; N=3; Terminated; Sponsor: GlaxoSmithKline; Phase classification: P1/2 ➔ P2

Clinical • Phase classification • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

Phase 1 dose escalating study to assess safety, tolerability, food effect and PK of CHR-5154 in healthy male volunteers (clinicaltrials.gov) - P1, N=94; Sponsor: GlaxoSmithKline; Recruiting; Phase shift: Preclinical -> P1.

Phase shift • Rheumatoid Arthritis